Novel agents in the management of lung cancer.

Hdl Handle:
http://hdl.handle.net/10147/206262
Title:
Novel agents in the management of lung cancer.
Authors:
Kennedy, B; Gargoum, F; Bystricky, B; Curran, D R; O'Connor, T M
Affiliation:
Department of Respiratory Medicine, Mercy University Hospital, Cork, Ireland.
Citation:
Curr Med Chem. 2010;17(35):4291-325.
Journal:
Current medicinal chemistry
Issue Date:
31-Jan-2012
URI:
http://hdl.handle.net/10147/206262
PubMed ID:
20939812
Abstract:
Lung cancer is the leading cause of cancer death worldwide. Survival remains poor as approximately 80% of cases present with advanced stage disease. However, new treatments are emerging which offer hope to patients with advanced disease. Insights into cell biology have identified numerous intracellular and extracellular peptides that are pivotal in cancer cell signalling. Disrupting the function of these peptides inhibits intracellular signal transduction and diminishes uncontrolled proliferation, resistance to apoptosis and tumour angiogenesis. The most widely studied signalling pathway is the Epidermal Growth Factor (EGF) pathway. EGF signalling can be disrupted at numerous points. Blockade of the cell surface receptor is achieved by the monoclonal antibody cetuximab; intracellular tyrosine kinase activity is inhibited by erlotinib. Vascular Endothelial Growth Factor (VEGF) regulates another pathway important for tumour growth. Inhibition of VEGF impairs angiogenesis and disrupts metastatic spread. Bevacizumab is a monoclonal antibody that binds to VEGF and blocks interaction with its cell surface receptor. Clinical trials have demonstrated that disruption of these signalling pathways can improve survival in advanced lung cancer. New compounds including folate antimetabolites such as pemetrexed, proteasome inhibitors such as bortezomib, modified glutathione analogues such as TLK286, and other agents such as epothilones and other small molecules are currently being evaluated in patients with lung cancer. As more and more signalling peptides are targeted for manipulation, it is hoped that a new era is dawning in the treatment of advanced stage lung cancer. This review will focus on emerging new therapies in the management of lung cancer.
Language:
eng
MeSH:
Antineoplastic Agents/chemistry/pharmacology/*therapeutic use; Epidermal Growth Factor/antagonists & inhibitors/metabolism; Humans; Lung Neoplasms/*drug therapy/metabolism; Molecular Structure; Signal Transduction/drug effects; Vascular Endothelial Growth Factor A/antagonists & inhibitors/metabolism
ISSN:
1875-533X (Electronic); 0929-8673 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorKennedy, Ben_GB
dc.contributor.authorGargoum, Fen_GB
dc.contributor.authorBystricky, Ben_GB
dc.contributor.authorCurran, D Ren_GB
dc.contributor.authorO'Connor, T Men_GB
dc.date.accessioned2012-01-31T16:39:07Z-
dc.date.available2012-01-31T16:39:07Z-
dc.date.issued2012-01-31T16:39:07Z-
dc.identifier.citationCurr Med Chem. 2010;17(35):4291-325.en_GB
dc.identifier.issn1875-533X (Electronic)en_GB
dc.identifier.issn0929-8673 (Linking)en_GB
dc.identifier.pmid20939812en_GB
dc.identifier.urihttp://hdl.handle.net/10147/206262-
dc.description.abstractLung cancer is the leading cause of cancer death worldwide. Survival remains poor as approximately 80% of cases present with advanced stage disease. However, new treatments are emerging which offer hope to patients with advanced disease. Insights into cell biology have identified numerous intracellular and extracellular peptides that are pivotal in cancer cell signalling. Disrupting the function of these peptides inhibits intracellular signal transduction and diminishes uncontrolled proliferation, resistance to apoptosis and tumour angiogenesis. The most widely studied signalling pathway is the Epidermal Growth Factor (EGF) pathway. EGF signalling can be disrupted at numerous points. Blockade of the cell surface receptor is achieved by the monoclonal antibody cetuximab; intracellular tyrosine kinase activity is inhibited by erlotinib. Vascular Endothelial Growth Factor (VEGF) regulates another pathway important for tumour growth. Inhibition of VEGF impairs angiogenesis and disrupts metastatic spread. Bevacizumab is a monoclonal antibody that binds to VEGF and blocks interaction with its cell surface receptor. Clinical trials have demonstrated that disruption of these signalling pathways can improve survival in advanced lung cancer. New compounds including folate antimetabolites such as pemetrexed, proteasome inhibitors such as bortezomib, modified glutathione analogues such as TLK286, and other agents such as epothilones and other small molecules are currently being evaluated in patients with lung cancer. As more and more signalling peptides are targeted for manipulation, it is hoped that a new era is dawning in the treatment of advanced stage lung cancer. This review will focus on emerging new therapies in the management of lung cancer.en_GB
dc.language.isoengen_GB
dc.subject.meshAntineoplastic Agents/chemistry/pharmacology/*therapeutic useen_GB
dc.subject.meshEpidermal Growth Factor/antagonists & inhibitors/metabolismen_GB
dc.subject.meshHumansen_GB
dc.subject.meshLung Neoplasms/*drug therapy/metabolismen_GB
dc.subject.meshMolecular Structureen_GB
dc.subject.meshSignal Transduction/drug effectsen_GB
dc.subject.meshVascular Endothelial Growth Factor A/antagonists & inhibitors/metabolismen_GB
dc.titleNovel agents in the management of lung cancer.en_GB
dc.contributor.departmentDepartment of Respiratory Medicine, Mercy University Hospital, Cork, Ireland.en_GB
dc.identifier.journalCurrent medicinal chemistryen_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.